Endocrine, Metabolic & Immune Disorders - Drug Targets

Author(s): Shufeng Yu, Ying Zhang, Zhihong Chen, Jiye Song and Caixia Wang*

DOI: 10.2174/1871530322666220607123739

A Novel Compound Heterozygous Gene Mutation of Dolichol Kinase Deficiency (DOLK-CDG)

Page: [235 - 241] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background: Congenital disorder of glycosylation caused by mutation of the DOLK(DOLK-CDG) is a group of rare autosomal recessive diseases with an early-onset age and poor prognosis. DOLK-CDG can cause the dysfunction of multiple systems and organs such as the heart, skin, nerves, and bones.

Case Presentation: We report a child with DOLK-CDG diagnosed and treated in the Affiliated Hospital of Qingdao University. The child was born with neonatal asphyxia, Ichthyoid rash, and congenital heart disease. His fingers of both the hands looked like lotus roots, and the palm and foot were covered by a white membrane. He was hospitalized with a severe infection at 4 months after birth. Physical examination showed that he was complicated with development delay and hypotonia. He experienced convulsions 1 hour after admission and died of multiple organ failure 2 hours after admission. Blood samples were taken for genetic testing before the child died. The results showed that there was a novel compound heterozygous mutation in DOLK, c.1268C>G (P.P423R) and c.1581_1583del (P.527_528del).

Conclusion: This mutation is new and not included in the human gene mutation library. The discovery of the novel mutation broadened the mutation spectrum of DOLK. At the same time, we sorted out the DOLK-CDG gene mutation sites and related clinical manifestations reported by August 2021 through a literature review.

Keywords: Dolichol kinase, congenital disorders of glycosylation, gene, mutation, Ichthyoid rash, congenital heart disease.

Graphical Abstract

[1]
Ondruskova, N.; Cechova, A.; Hansikova, H.; Honzik, T.; Jaeken, J. Congenital disorders of glycosylation: Still “hot” in 2020. Biochim. Biophys. Acta, Gen. Subj., 2021, 1865(1), 129751.
[http://dx.doi.org/10.1016/j.bbagen.2020.129751] [PMID: 32991969]
[2]
Lefeber, D.J.; de Brouwer, A.P.M.; Morava, E.; Riemersma, M.; Schuurs-Hoeijmakers, J.H.M.; Absmanner, B.; Verrijp, K.; van den Akker, W.M.; Huijben, K.; Steenbergen, G.; van Reeuwijk, J.; Jozwiak, A.; Zucker, N.; Lorber, A.; Lammens, M.; Knopf, C.; van Bokhoven, H.; Grünewald, S.; Lehle, L.; Kapusta, L.; Mandel, H.; Wevers, R.A. Autosomal recessive dilated cardiomyopathy due to DOLK mutations results from abnormal dystroglycan O-mannosylation. PLoS Genet., 2011, 7(12), e1002427.
[http://dx.doi.org/10.1371/journal.pgen.1002427] [PMID: 22242004]
[3]
Rush, E.T.; Baker, C.V.; Rizzo, W.B. Dolichol kinase deficiency (DOLK-CDG): Two new cases and expansion of phenotype. Am. J. Med. Genet. A., 2017, 173(9), 2428-2434.
[http://dx.doi.org/10.1002/ajmg.a.38287] [PMID: 28816422]
[4]
Helander, A.; Stödberg, T.; Jaeken, J.; Matthijs, G.; Eriksson, M.; Eggertsen, G. Dolichol kinase deficiency (DOLK-CDG) with a purely neurological presentation caused by a novel mutation. Mol. Genet. Metab., 2013, 110(3), 342-344.
[http://dx.doi.org/10.1016/j.ymgme.2013.07.002] [PMID: 23890587]
[5]
Kranz, C.; Jungeblut, C.; Denecke, J.; Erlekotte, A.; Sohlbach, C.; Debus, V.; Kehl, H.G.; Harms, E.; Reith, A.; Reichel, S.; Grobe, H.; Hammersen, G.; Schwarzer, U.; Marquardt, T. A defect in dolichol phosphate biosynthesis causes a new inherited disorder with death in early infancy. Am. J. Hum. Genet., 2007, 80(3), 433-440.
[http://dx.doi.org/10.1086/512130] [PMID: 17273964]
[6]
Lieu, M.T.; Ng, B.G.; Rush, J.S.; Wood, T.; Basehore, M.J.; Hegde, M.; Chang, R.C.; Abdenur, J.E.; Freeze, H.H.; Wang, R.Y. Severe, fatal multisystem manifestations in a patient with dolichol kinasecongenital disorder of glycosylation. Mol. Genet. Metab., 2013, 110(4), 484-489.
[http://dx.doi.org/10.1016/j.ymgme.2013.09.016] [PMID: 24144945]
[7]
Bryan, D.H.; Roger, E.S.; Julie, R.J. Fatal hyperkeratosis syndrome in four siblings due to dolichol kinase deficiency. Am. J. Med. Genet. A., 2020, 182A(6), 1421-1425.
[http://dx.doi.org/10.1002/ajmg.a.61574]
[8]
Medrano, C.; Vega, A.; Navarrete, R.; Ecay, M.J.; Calvo, R.; Pascual, S.I.; Ruiz-Pons, M.; Toledo, L.; García-Jiménez, I.; Arroyo, I.; Campo, A.; Couce, M.L.; Domingo-Jiménez, M.R.; García-Silva, M.T.; González-Gutiérrez-Solana, L.; Hierro, L.; Martín-Hernández, E.; Martínez-Pardo, M.; Roldán, S.; Tomás, M.; Cabrera, J.C.; Mártinez-Bugallo, F.; Martín-Viota, L.; Vitoria-Miñana, I.; Lefeber, D.J.; Girós, M.L.; Serrano Gimare, M.; Ugarte, M.; Pérez, B.; Pérez-Cerdá, C. Clinical and molecular diagnosis of non-phosphomannomutase 2 N-linked congenital disorders of glycosylation in Spain. Clin. Genet., 2019, 95(5), 615-626.
[http://dx.doi.org/10.1111/cge.13508] [PMID: 30653653]
[9]
García-Silva, M.T.; Matthijs, G.; Schollen, E.; Cabrera, J.C.; Sanchez del Pozo, J.; Martí Herreros, M.; Simón, R.; Maties, M.; Martín Hernández, E.; Hennet, T.; Briones, P. Congenital disorder of glycosylation (CDG) type Ie. A new patient. J. Inherit. Metab. Dis., 2004, 27(5), 591-600.
[http://dx.doi.org/10.1023/B:BOLI.0000042984.42433.d8] [PMID: 15669674]
[10]
Haeuptle, M.A.; Hennet, T. Congenital disorders of glycosylation: An update on defects affecting the biosynthesis of dolichol-linked oligosaccharides. Hum. Mutat., 2009, 30(12), 1628-1641.
[http://dx.doi.org/10.1002/humu.21126] [PMID: 19862844]
[11]
Jones, J.; Krag, S.S.; Betenbaugh, M.J. Controlling N-linked glycan site occupancy. Biochim. Biophys. Acta, 2005, 1726(2), 121-137.
[http://dx.doi.org/10.1016/j.bbagen.2005.07.003] [PMID: 16126345]
[12]
Mazzarotto, F.; Tayal, U.; Buchan, R.J.; Midwinter, W.; Wilk, A.; Whiffin, N.; Govind, R.; Mazaika, E.; de Marvao, A.; Dawes, T.J.W.; Felkin, L.E.; Ahmad, M.; Theotokis, P.I.; Ed-wards, E.; Ing, A.Y.; Thomson, K.L.; Chan, L.L.H.; Sim, D.; Baksi, A.J.; Pantazis, A.; Roberts, A.M.; Watkins, H.; Funke, B.; O’Regan, D.P.; Olivotto, I.; Barton, P.J.R.; Prasad, S.K.; Cook, S.A.; Ware, J.S.; Walsh, R. Reevaluating the genetic contribution of monogenic dilated cardiomyopathy. Circulation, 2020, 141(5), 387-398.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.037661] [PMID: 31983221]
[13]
Neubauer, J.; Lecca, M.R.; Russo, G.; Bartsch, C.; Medeiros-Domingo, A.; Berger, W.; Haas, C. Post-mortem whole-exome analysis in a large sudden infant death syndrome cohort with a focus on cardiovascular and metabolic genetic diseases. Eur. J. Hum. Genet., 2017, 25(4), 404-409.
[http://dx.doi.org/10.1038/ejhg.2016.199] [PMID: 28074886]
[14]
Morena-Barrio, M.E.L.; Ballesta-Martínez, M.J.; López-Gálvez, R. Genetic predisposition to fetal alcohol syndrome: Association with congenital disorders of N-glycosylation. Pediatr. Res., 2018, 83(1-1), 119-127.
[http://dx.doi.org/10.1038/pr.2017.201]
[15]
Peng, J.; Pang, N.; Wang, Y.; Wang, X.L.; Chen, J.; Xiong, J.; Peng, P.; Zhu, C.H.; Kessi, M.B.; He, F.; Yin, F. Next-generation sequencing improves treatment efficacy and reduces hospitalization in children with drug-resistant epilepsy. CNS Neurosci. Ther., 2019, 25(1), 14-20.
[http://dx.doi.org/10.1111/cns.12869] [PMID: 29933521]
[16]
Lefeber, D.J.; Schönberger, J.; Morava, E.; Guillard, M.; Huyben, K.M.; Verrijp, K.; Grafakou, O.; Evangeliou, A.; Preijers, F.W.; Manta, P.; Yildiz, J.; Grünewald, S.; Spilioti, M.; van den Elzen, C.; Klein, D.; Hess, D.; Ashida, H.; Hofsteenge, J.; Maeda, Y.; van den Heuvel, L.; Lammens, M.; Lehle, L.; Wevers, R.A. Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies. Am. J. Hum. Genet., 2009, 85(1), 76-86.
[http://dx.doi.org/10.1016/j.ajhg.2009.06.006] [PMID: 19576565]
[17]
Michele, D.E.; Kabaeva, Z.; Davis, S.L.; Weiss, R.M.; Campbell, K.P. Dystroglycan matrix receptor function in cardiac myocytes is important for limiting activity-induced myocardial damage. Circ. Res., 2009, 105(10), 984-993.
[http://dx.doi.org/10.1161/CIRCRESAHA.109.199489] [PMID: 19797173]